Skip to main content
Premium Trial:

Request an Annual Quote

BG Medicine Amends Galectin-3 Test Sales Agreement With Abbott

NEW YORK (GenomeWeb) – BG Medicine said today that it has amended its agreement with Abbott Laboratories for licensing and distributing its galectin-3 test.

The amendment changes product fees Abbott pays to BG Medicine for galectin-3 tests it sells to reference laboratories. In addition, Abbott was to make a payment of $500,000 to BG Medicine by November 30 and will make another $500,000 payment by June 30, 2016, provided certain commercial milestones are met.

BG said it expects that the modified agreement will help expedite the transition of its galectin-3 test from manual to automated platforms. Currently, the company derives the bulk of its revenues from manual testing, but it aims to move to automated testing.

Moving galectin-3 testing to an automated platform has long been a key part of BG Medicine’s commercial strategy. The company expects that such a move would increase uptake of the test by improving throughput and turnaround time and reducing the amount of labor involved in running it.

In addition to Abbott, the company has partnered with Alere, Siemens, and BioMérieux on developing automated versions of the test.

The amendments to the Abbott agreement cover only sales of the galectin-3 test to reference labs. Product fees will remain the same for sales to other customer segments.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more